Disclosed is a computer-implemented method for determining a measure correlated to the probability that two mutated sequence reads derive from the same sequence comprising mutations. The method comprises receiving mutated sequence reads each corresponding to a subsequence of a sequence comprising mutations compared to a sequence not comprising mutations, applying a common minimizer function to each mutated sequence read, to determining minimizers for each mutated sequence read, determining positions of the one or more minimizers in each mutated sequence read, determining positions of mutations in each mutated sequence read, and for at least two mutated sequence reads with a common minimizer, counting the number of mutations with matching position and/or mismatching position when the respective minimizers are aligned. Also disclosed is a corresponding method for determining at least a portion of a sequence of at least one target template nucleic acid molecule.

The present invention provides a simple and highly accurate method for an ecological survey with low environmental burden, more specifically, a method for analyzing biological species living in a water environment. The method assesses biological species living in the water environment quantitatively and further identify them exhaustively by analyzing RNA contained in the water environment.

The present invention provides a simple and highly accurate method for an ecological survey with low environmental burden, more specifically, a method for analyzing biological species living in a water environment. The method assesses biological species living in the water environment quantitatively and further identify them exhaustively by analyzing RNA contained in the water environment.

The disclosure provides a method for or the early diagnosis, prognosis and differentiation of myocardial infarction (MI). The method comprises performing genetic analysis on gut microbiota. The disclosure also provides a biomarker and kit for the early diagnosis, prognosis, recurrence and differentiation of MI.

Detection of viral nucleic acids (NAs) and their variants is effected using nanopore technology. If the target wild type viral NA is single-stranded, it is mixed with its complementary NA, and also the unknown viral NA sample to be analyzed, followed by hybridization; while if the target wild type viral NA is double-stranded, it is mixed with the unknown viral NA sample only, then denatured and followed by hybridization. The hybridized products from either case are then subjected to translocation in the form of a translocation analysis, experiment or test through a nanopore device that measures the electrical signals induced through translocation events. The corresponding signal train is characteristic of an individual virus or variant and acts as a “fingerprint” facilitating rapid virus identification and discovery of a new variant.

Detection of viral nucleic acids (NAs) and their variants is effected using nanopore technology. If the target wild type viral NA is single-stranded, it is mixed with its complementary NA, and also the unknown viral NA sample to be analyzed, followed by hybridization; while if the target wild type viral NA is double-stranded, it is mixed with the unknown viral NA sample only, then denatured and followed by hybridization. The hybridized products from either case are then subjected to translocation in the form of a translocation analysis, experiment or test through a nanopore device that measures the electrical signals induced through translocation events. The corresponding signal train is characteristic of an individual virus or variant and acts as a “fingerprint” facilitating rapid virus identification and discovery of a new variant.

Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.

Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.

A method of distinguishing a subject with pre-clinical Alzheimer's disease from those with similar symptoms but other forms of dementia such as mild cognitive impairment. The blood RNA whole transcriptome profile of a subject with suspected pre-clinical Alzheimer's disease is obtained and analyzed against a reference blood RNA whole transcriptome profile from a subject with another form of dementia such as frontal temporal dementia, CADASIL or mild cognitive impairment (MCI). The blood RNA whole transcriptome profile includes the presence and quantitation of ncRNA. Methods to enhance treatment of epileptic seizures are also discussed.

A method of distinguishing a subject with pre-clinical Alzheimer's disease from those with similar symptoms but other forms of dementia such as mild cognitive impairment. The blood RNA whole transcriptome profile of a subject with suspected pre-clinical Alzheimer's disease is obtained and analyzed against a reference blood RNA whole transcriptome profile from a subject with another form of dementia such as frontal temporal dementia, CADASIL or mild cognitive impairment (MCI). The blood RNA whole transcriptome profile includes the presence and quantitation of ncRNA. Methods to enhance treatment of epileptic seizures are also discussed.